


曾令民 主任--[我要掛號](#)



專  
長:

- 1.乳房疾病治療
- 2.臨床試驗暨基礎醫學研究
- 3.內分泌外科

現  
職:

- 1.國立陽明大學 外科學系教授
- 2.臺北榮民總醫院乳房醫學中心 主任
- 3.臺北榮民總醫院實驗外科 主任
- 4.臺北榮民總醫院一般外科 主治醫師
- 5.臺灣乳房醫學會 理事長
- 6.臺灣內分泌外科醫學會 理事

學  
歷:

國防醫學院醫學系

經  
歷:

國立陽明大學醫學院 外科學系副  
教授  
國防醫院外科 外科副教授  
美國德州休士頓 MD Anderson 癌  
病中心研究員  
臺灣乳房醫學會 秘書長  
臺灣內分泌外科醫學會 秘書長  
中華民國癌症醫學會及台灣外科醫  
學會腫瘤外科專科醫師-訓練指導  
醫師  
臺灣癌症臨床研究合作組織乳癌研  
究委員

## Publications in 5 years (\*correspondence):

1. Chou WC, Hsiung CN, Chen WT, **Tseng LM**, Wang HC, Chu HW, Hou MF, Yu JC, Shen CY. A functional variant near XCL1 gene improves breast cancer survival via promoting cancer immunity. *Int J Cancer*. 2020 Jan 6. doi: 10.1002/ijc.32855. [Epub ahead of print]
2. Huang JY, Wang YY, Lo S, **Tseng LM**, Chen DR, Wu YC, Hou MF, Yuan SF. Visfatin Mediates Malignant Behaviors through Adipose-Derived Stem Cells Intermediary in Breast Cancer. *Cancers (Basel)*. 2019 Dec 20;12(1). pii: E29. doi: 10.3390/cancers12010029.
3. Chen K, Feng CJ, Ma H, Hsiao FY, **Tseng LM**, Tsai YF, Lin YS, Huang LY, Yu WC, Perng CK. Preoperative Breast Volume Evaluation of One Stage Immediate Breast Reconstruction using 3-Dimensional Surface Imaging and a Printed Mold. *J Chin Med Assoc. J Chin Med Assoc*. 2019 Sep;82(9):732-739. doi: 10.1097/JCMA.000000000000155. [Epub ahead of print]
4. Huang SM, **Tseng LM**, Lai JC, Lien PJ, Chen PH. Infertility-related knowledge in childbearing-age women with breast cancer after chemotherapy. *Int J Nurs Pract*. 2019 Jul 16:e12765. doi: 10.1111/ijn.12765. [Epub ahead of print]
5. Huang SM, **Tseng LM**, Lai JC, Lien PJ, Chen PH. Oncofertility to Evidence-Based Practice: Changes in Fertility Intention and Symptom Burden in Reproductive-Age Women With Breast Cancer. *Worldviews Evid Based Nurs*. 2019 May 31.
6. Tsai HY, Fu SL, **Tseng LM**, Chiu JH, Lin CH. hnRNP K S379 phosphorylation participates in migration regulation of triple negative MDA-MB-231 cells. *Sci Rep*. 2019 May 20;9(1):7611.
7. Lin YS, Chiu YC, Tsai YH, Tsai YF, Wang JY, **Tseng LM**, Chiu JH. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines. *J Cell Biochem*. 2019 Aug;120(8):13531-13544. doi: 10.1002/jcb.28628. Epub 2019 Apr 7.
8. Lee TI, Sheu SJ, Chang HC, Hung YT, **Tseng LM**, Chou SS, Liang TH, Liu HJ, Lu HL, Chen MC, Liu YC, Tsai CS, Sun JC. Developing a Web-Based Comic for Newly Diagnosed Women With Breast Cancer: An Action Research Approach. *J Med Internet Res*. 2019 Feb 4;21(2):e10716.
9. Hung YT, Wu CF, Liang TH, Chou SS, Chen GL, Wu PN, Su GR, Jang TH, Liu CY, Wang CY, **Tseng LM\***, Sheu SJ\*. Developing a Decision-Aid Website for Breast Cancer Surgery: An Action Research Approach. *J Med Internet Res*. 2019 Feb 4;21(2):e10404. doi: 10.2196/10404. (IF=4.671 ; 2017)
10. Liu CY, Chu PY, Huang CT, Chen JL, Yang HP, Wang WL, Lau KY, Lee CH, Lan TY, Huang TT, Lin PH, Dai MS, **Tseng LM**. Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells. *Cancers (Basel)*. 2019 Jan 17;11(1). pii: E105. doi: 10.3390/cancers11010105.
11. Liu CY, Huang TT, Chen YT, Chen JL, Chu PY, Huang CT, Wang WL, Lau KY, Dai MS, Shiao CW, **Tseng LM\***. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression. *EBioMedicine*. 2019 Feb;40:263-275 (IF=6.183 ; 2017)
12. Tsai YF, **Tseng LM**, Lien PJ, Hsu CY, Lin YS, King KL, Wang YL, Chao TC, Liu CY, Chiu JH, Yang MH. HER2 immunohistochemical scores provide prognostic information for patients with HER2-type invasive breast cancer. *Histopathology*. 2019 Mar;74(4):578-586. doi: 10.1111/his.13801. Epub 2019 Jan 29.
13. Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, **Tseng LM**, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. *Eur J Cancer*. 2018 Nov;103:147-154. doi: 10.1016/j.ejca.2018.08.002. Epub 2018 Sep 18.

14. Huang YH, Chu PY, Chen JL, Huang CT, Lee CH, Lau KY, Wang WL, Wang YL, Lien PJ, **Tseng LM\***, Liu CY\*. SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment. *J Clin Med.* 2018 Aug 28;7(9) (IF=5.583 ; R/C=73/107 , 2017)
15. Huang SM, **Tseng LM**, Lai JC, Tsai YF, Lien PJ, Chen PH. Impact of Symptom and Social Support on Fertility Intention in Reproductive-Age Women With Breast Cancer. *Clin Nurs Res.* 2018 Apr 1:1054773818770814. doi: 10.1177/1054773818770814. (IF=1.466 ; R/C=73/107 , NURSING - SCIE , 2017)
16. Chen MS, Wang SF, Hsu CY, Yin PH, Yeh TS, Lee HC\*, **Tseng LM\***. CHAC1 degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-eIF2 $\alpha$ -ATF4 pathway. *Oncotarget.* 2017 Dec 9;8(70):114588-114602.
17. Liu CY, Lau KY, Hsu CC, Chen JL, Lee CH, Huang TT, Chen YT, Huang CT, Lin PH, **Tseng LM\***. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. *PLoS One.* 2017 Dec 20;12(12):e0189007. doi: 10.1371/journal.pone.0189007. eCollection 2017. (IF=2.766, 15/64, MULTIDISCIPLINARY SCIENCES E, 2017)
18. Sung PL, Wen KC, Chen YJ, Chao TC, Tsai YF, **Tseng LM**, Qiu JT, Chao KC, Wu HH, Chuang CM, Wang PH, Huang CF. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels. *PLoS One.* 2017 Sep 29;12(9):e0185615. doi: 10.1371/journal.pone.0185615. eCollection 2017. (IF=2.766, 15/64, MULTIDISCIPLINARY SCIENCES E, 2017)
19. Liu CY, Wu CY, Petrossian K, Huang TT, **Tseng LM**, Chen S. Treatment for the endocrine resistant breast cancer: Current options and future perspectives. *J Steroid Biochem Mol Biol.* 2017 Sep;172:166-175. (I F=4.095 ; R/C=69/292 , BIOCHEMISTRY & MOLECULAR BIOLOGY , 2017)
20. Chiu JH, Chen FP, Tsai YF, Lin MT, **Tseng LM\***, Shyr YM. Effects of Chinese medicinal herbs on expression of brain-derived Neurotrophic factor (BDNF) and its interaction with human breast cancer MDA-MB-231 cells and endothelial HUVECs. *BMC Complement Altern Med.* 2017 Aug 12;17(1):401. (IF=2.109, 8/27, INTEGRATIVE & COMPLEMENTARY MEDICINE, 2017)
21. Liu CY, Huang TT, Chu PY, Huang CT, Lee CH, Wang WL, Lau KY, Tsai WC, Chao TI, Su JC, Chen MH, Shiao CW, **Tseng LM\***, Chen KF. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells. *Exp Mol Med.* 2017 Aug 11;49(8):e366 (IF=5.584, 15/133, MEDICINE, RESEARCH & EXPERIMENTAL, 2017)
22. Tsai YF, **Tseng LM\***, Hsu CY, Yang MH, Chiu JH\*, Shyr YM. Brain-derived neurotrophic factor (BDNF) -TrkB signaling modulates cancer-endothelial cells interaction and affects the outcomes of triple negative breast cancer. *PLoS One.* 2017 Jun 12;12(6):e0178173. doi:10.1371/journal.pone.0178173. eCollection 2017. (IF=2.766, 15/64, MULTIDISCIPLINARY SCIENCES E, 2017)
23. Chen PM, Chu PY, Tung SL, Liu CY, Tsai YF, Lin YS, Wang WL, Wang YL, Lien PJ, Chao TC, **Tseng LM\***. Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up. *Hum Pathol.* 2017 Aug;66:93-100. doi: 10.1016/j.humpath.2017.06.001. Epub 2017 Jun 9. (IF=3.125, 19/79, PATHOLOGY, 2017)
24. Liu CY, Chen KF, Chao TI, Chu PY, Huang CT, Huang TT, Yang HP, Wang WL, Lee CH, Lau KY, Tsai WC, Su JC, Wu CY, Chen MH, Shiao CW, **Tseng LM\***. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. *J Mol Med (Berl).* 2017 Sep;95(9):965-975. doi: 10.1007/s00109-017-1549-x. Epub 2017 Jun 4. (IF=4.938, 20/133, MEDICINE, RESEARCH & EXPERIMENTAL, 2017)
25. Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y,

- Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, **Tseng LM**, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30. (IF=36.418 3/222, ONCOLOGY, 2017)
26. Chiu JH, Wen CS, Wang JY, Hsu CY, Tsai YF, Hung SC, **Tseng LM\***, Shyr YM. Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers. *J Transl Med.* 2017 May 4;15(1):97. doi: 10.1186/s12967-017-1192-x. (IF=4.197, 28/133, MEDICINE, RESEARCH & EXPERIMENTAL, 2017)
27. Toi M, Shao Z, Hurvitz S, **Tseng LM**, Zhang Q, Shen K, Liu D, Feng J, Xu B, Wang X, Lee KS, Ng TY, Ridolfi A, Noel-Baron F, Ringeisen F, Jiang Z. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. *Breast Cancer Res.* 2017 Apr 11;19(1):47. (IF=6.142, 34/222, ONCOLOGY, 2017)
28. **Tseng LM\***, Chiu JH, Liu CY, Tsai YF, Wang YL, Yang CW, Shyr YM. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women *Breast Cancer Res Treat.* 2017 Jun;163(2):241-254. (IF=3.605, 88/222, ONCOLOGY, 2017)
29. Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, **Tseng LM**, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2 positive breast cancer. *Breast Cancer Res.* 2017 Feb 9;19(1):16. (IF=6.142, 34/222, ONCOLOGY, 2017)
30. Liu CY, Su JC, Huang TT, Chu PY, Huang CT, Wang WL, Lee CH, Lau KY, Tsai WC, Yang HP, Shiau CW, **Tseng LM\***, Chen KF\*. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells. *Mol Oncol.* 2017 Mar;11(3):266-279. Epub 2017 Feb 7. (IF=5.264, 46/222, ONCOLOGY, 2017)
31. Liu CY, Huang TT, Huang CT, Hu MH, Wang DS, Wang WL, Tsai WC, Lee CH, Lau KY, Yang HP, Chen MH, Shiau CW, **Tseng LM\***, Chen KF\*. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. *Eur J Cancer.* 2017 Feb;72:112-123 (IF=7.191,25/222, ONCOLOGY, 2017)
32. Yeh TC, Huang TT, Yeh TS, Chen YR, Hsu KW, Yin PH, Lee HC, **Tseng LM\***. miR-151-3p Targets TWIST1 to Repress Migration of Human Breast Cancer Cells. *PLoS One.* 2016 ec;11(12):e0168171. (IF=2.766, 15/64, MULTIDISCIPLINARY SCIENCES E, 2017)
33. Huang SM, Hsieh PL, Hsiung Y, **Tseng LM**, Chen PH, Hung CT Decision-Making Process Regarding Fertility Among Reproductive-Age Women With Cancer in Taiwan. *Cancer Nurs.* 2016 Oct 6. [Epub ahead of print] . (IF=1.844, 183/222, ONCOLOGY, 2017)
34. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, **Tseng LM**, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. *N Engl J Med.* 2016 Nov 3;375(18):1738-1748. (IF=79.258, 1/154, MEDICINE, GENERAL & INTERNAL, 2017)
35. Chen YY, **Tseng LM**, Yang CF, Lien PJ, Hsu CY. Adjust cut-off values of immunohistochemistry models to predict risk of distant recurrence in invasive breast carcinoma patients. *J Chin Med Assoc.* 2016 Dec;79(12):649-655. doi: 10.1016/j.jcma.2016.06.004. Epub 2016 Aug 29 (IF=1.660, 72/154, MEDICINE, GENERAL & INTERNAL, 2017)
36. Su JC, Mar AC, Wu SH, Tai WT, Chu PY, Wu CY, **Tseng LM**, Lee TC, Chen KF, Liu CY, Chiu HC, Shiau

- CW. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. *Sci Rep*. 2016 Jul 1;6:28888. (IF=4.122, 12/64, MULTIDISCIPLINARY SCIENCES, 2017)
37. Gianni L, Pienkowski T, Im YH, **Tseng LM**, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *Lancet Oncol*. 2016 Jun;17(6):791-800 (IF=36.418, 3/222, ONCOLOGY, 2017)
38. André F, Hurvitz S, Fasolo A, **Tseng LM**, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H2, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. *J Clin Oncol*. 2016 Jun 20;34(18):2115-24 (IF=26.303, 4/222, ONCOLOGY, 2017)
39. Hsu CC, **Tseng LM**, Lee HC. Role of mitochondrial dysfunction in cancer progression *Exp Biol Med (Maywood)*. 2016 Jun;241(12):1281-95. (IF=2.413, 76/133, MEDICINE, GENERAL & INTERNAL, 2017)
40. Huang SM, **Tseng LM\***, Chien LY, Tai CJ, Chen PH, Hung CT, Hsiung Y. Effects of non-sporting and sporting qigong on frailty and quality of life among breast cancer patients receiving chemotherapy. *Eur J Oncol Nurs*. 2016 Apr;21:257-65. (IF=1.812 ; R/C=184/222 , Oncology , 2017)
41. Tsai CH, Chiu JH, Yang CW, Wang JY, Tsai YF, **Tseng LM\***, Chen WS, Shyr YM. Molecular characteristics of recurrent triple-negative breast cancer. *Mol Med Rep*. 2015 Nov;12(5):7326-34. doi: 10.3892/mmr.2015.4360. Epub 2015 Sep 24. (IF=1.922 ; R/C=179/222 , Oncology , 2017)
42. Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, **Tseng LM**, Liu MC, Lluch A, Galeota E, Magazzù D, de la Haba-Rodríguez J, Oh DY, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. *Ann Oncol*. 2015 Dec;26(12):2429-36 (IF= 13.926, R/C=9/222 , Oncology , 2017)
43. Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. *Mod Pathol*. 2015 Sep;28(9):1185-201 doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24. (IF= 6.655, R/C=3/79 , PATHOLOGY , 2017)
44. Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, **Tseng LM**, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. *Lancet Oncol*. 2015 Jul;16(7):816-29. doi: 10.1016/S1470-2045(15)00051-0. Epub 2015 Jun 1 (IF=36.418, 3/222, ONCOLOGY, 2017)
45. Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. *Ann Oncol*. Epub 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. (IF= 13.926, R/C=9/222 , Oncology , 2017)

- 46 Liang SY, Chao TC, **Tseng LM**, Tsay SL, Lin KC, Tung HH. Symptom-Management Self-efficacy Mediates the Effects of Symptom Distress on the Quality of Life Among Taiwanese Oncology Outpatients With Breast Cancer. *Cancer Nurs. Epub 2015 Feb 27* Jan-Feb;39(1):67-73 (IF=1.844, 183/222, ONCOLOGY, 2017)
- 47 Lu YS, Chen TW, Lin CH, Yeh DC, **Tseng LM**, Wu PF, Rau KM, Chen BB, Chao TC, Huang SM, Huang CS, Shih TT, Cheng AL. Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. *Clin Cancer Res. 2015 Apr 15;21(8):1851-8 Epub 2015 Feb 19* (IF=10.199, R/C=12/222, ONCOLOGY, 2017)
- 48 Yang MY, Chen MT, Huang PI, Wang CY, Chang YC, Yang YP, Lo WL, Sung WH, Liao YW, Lee YY, Chang YL, **Tseng LM**, Chen YW, Ma HI. Nuclear Localization Signal-Enhanced Polyurethane-Short Branch Polyethylenimine-Mediated Delivery of Let-7a Inhibited Cancer Stem-Like Properties by Targeting the 3'-UTR of HMGA2 in Anaplastic Astrocytoma. *Cell Transplant. 2015;24(8):1431-50. Epub 2014 Jun 3.* (IF=2.885, R/C=62/133, MEDICINE, RESEARCH & EXPERIMENTAL, 2017)